Showing 4701-4710 of 5806 results for "".
- FDA Approves Merck’s Keytruda for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Not Curable by Surgery or Radiationhttps://practicaldermatology.com/news/fda-approves-mercks-keytruda-for-recurrent-or-metastatic-cutaneous-squamous-cell-carcinoma-not-curable-by-surgery-or-radiation/2460445/The FDA has approved Keytruda, Merck’s anti-PD-1 therapy, in both three and six week dosing options as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
- FDA Approves New Dupixent Pre-filled Pen Designed to Support More Convenient Self-Administrationhttps://practicaldermatology.com/news/fda-approves-new-dupixent-pre-filled-pen-designed-to-support-more-convenient-self-administration/2460444/The FDA has approved a 300mg single-dose pre-filled pen for Regeneron Pharmaceuticals, Inc. and Sanofi's Dupixent (dupilumab). The pre-filled pen is approved for all Dupixent indications in patients aged 12 years and older, which includes use in certain patients with atopic dermatitis, asthma
- Tralokinumab Achieves Primary and Secondary Endpoints in Three pivotal Phase 3 Trials for ADhttps://practicaldermatology.com/news/tralokinumab-achieves-primary-and-secondary-endpoints-in-three-pivotal-phase-3-trials-for-ad/2460440/LEO Pharma A/S, shared results showing that tralokinumab 300mg, administered subcutaneously every two weeks, demonstrated efficacy and safety with or without concomitant use of a topical corticosteroid (TCS) in three Phase 3 trials (ECZTRA 1-3) for the treatment of adults with moderate to severe
- Abbvie's RINVOQ Improves Skin Clearance and Itch in First Phase 3 Study for ADhttps://practicaldermatology.com/news/abbvies-rinvoq-improves-skin-clearance-and-itch-in-first-phase-3-study-for-ad/2460439/AbbVie’s RINVOQ (upadacitinib) performed well in Measure Up 1, the first Phase 3 study to evaluate its efficacy and safety for the treatment of moderate-to-severe atopic dermatitis. Full results from Measure Up 1 will be presented at a future medical meeting and published in a pee
- Physician-Created App Unveils Remote Check-In Feature to Prevent Spread of COVID-19 in Medical Practiceshttps://practicaldermatology.com/news/physician-created-app-unveils-remote-check-in-feature-to-prevent-spread-of-covid-19-in-medical-practices/2460436/DocClocker, an app that allows patients to receive real-time wait time reporting of their medical providers, enabling patients to avoid long waits in medical waiting rooms—limiting COVID-19 exposure risks. The company recently launched a new feature for the app—DocClocker Remote Check
- Secondary Efficacy and Patient-Reported Outcomes in Phase 2b Clinical Trial of Tapinarof Cream for Atopic Dermatitishttps://practicaldermatology.com/news/secondary-efficacy-and-patient-reported-outcomes-in-phase-2b-clinical-trial-of-tapinarof-cream-for-atopic-dermatitis/2460435/Secondary efficacy and patient-reported outcomes from Dermavant's Phase 2b randomized clinical trial of tapinarof cream for the treatment of atopic dermatitis were recently reported in The Journal of the American Academy of Dermatology (JAAD). Tapinarof cream is a potential first-in-class, on
- AAD Survey: Parents Get the Importance of Sunscreen for their Kidshttps://practicaldermatology.com/news/aad-survey-parents-get-the-importance-of-sunscreen-for-their-kids/2460433/Fully 74 percent of parents today worry about sun protection more with their children than their parents did with them, and 90 percent of parents believe it’s important to teach their children healthy habits now so they will keep them when they are adults, finds a new survey from the Americ
- Regenerative Medicine Business News: Bimini Acquires Healeonhttps://practicaldermatology.com/news/regenerative-medicine-business-news-bimini-acquires-healeon/2460432/Bimini Health Tech has acquired Healeon Medical, Inc., a company that designs, develops, manufactures, and markets medical devices for autologous, point-of-care treatments. Healeon's products include: the signature HD PRP system which fe
- New Phase 3 Data for Tremfya Show Consistent, High Levels of Skin Clearance Through Four Years in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/new-phase-3-data-for-tremfya-show-consistent-high-levels-of-skin-clearance-through-four-years-in-moderate-to-severe-plaque-psoriasis/2460431/New long-term plaque psoriasis data for The Janssen Pharmaceutical Companies of Johnson & Johnson's Tremfya (guselkumab) show consistent, high levels of skin clearance at week 100 and week 204 (four years). In the open-label extension of VOYAGE 2, at four years, 80 percent of pa
- Johnson & Johnson Consumer Health Research Sheds Light on the Development of the Skin Microbiomehttps://practicaldermatology.com/news/johnson-johnson-consumer-health-research-sheds-light-on-the-development-of-the-skin-microbiome/2460428/New Johnson & Johnson Consumer Health research provides key insights into how the infant microbiome develops from birth to childhood. The findings, based on 10 years of data, were presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020.